文献速递生殖医学

欧洲人类遗传学与生殖学会关于医学辅助生殖中扩展性携带者筛查实践的调查

An ESHG-ESHRE survey on the current practice of expanded carrier screening in medically assisted reproduction.
PubMed 文献 · Hum Reprod · 2024-01-01

该横断面调查通过在线问卷收集欧洲医学辅助生殖领域专业人员对扩展性携带者筛查(ECS)的实践与观点,共299份有效回复来自40个国家。结果显示仅42.5%(127/299)的回复者所属中心提供ECS,各中心在检测面板、报告变异类型、费用和咨询等方面存在较大差异,不提供ECS的主要原因是缺乏专业推荐和高昂费用。

要点

  • 42.5%(127/299)的回复者所属中心提供ECS,实践差异较大。
  • 提供ECS的中心中,近45%(39/87)仅提供单一ECS面板。
  • 不提供ECS的主要原因为缺乏专业推荐(52.5%,73/139)和费用高或无报销(49.6%,69/139)。

核心结论

  • 研究显示对ECS的支持有限,不足半数回复者所属中心提供ECS,且欧洲各中心实践存在显著差异。
  • 结果强调需要促进关于在医学辅助生殖中实施ECS的利弊的更多循证讨论。

研究设计与样本

  • 横断面调查,使用在线SurveyMonkey工具设计问卷,评估欧洲医学辅助生殖实践中的当前做法与观点。
  • 调查于2022年2月8日至2022年4月11日进行,共收集338份回复;排除39份不完整回复后,最终分析纳入来自40个不同国家的299份回复。
  • 问卷通过ESHRE中央办公室(发送4889封邮件)和ESHG中央办公室(发送1790封邮件)向成员发送邀请,并通过社交媒体发布。

主要发现

  • 42.5%(127/299)的回复者所属中心提供ECS。
  • 提供ECS的中心中,近45%(39/87)提供单一ECS面板,25.3%(22/87)提供多种ECS面板选择,29.9%(26/87)提供全外显子组测序和大规模电子面板。
  • 81.8%(72/88)的回复者表示其提供的面板为通用型并覆盖全人群。
  • 在自体配子行医学辅助生殖的个体和夫妇中,ECS报告纳入致病性变异(89.7%,70/78)和可能致病性变异(64.1%,50/78)。
  • 87.9%(80/91)的回复者表示患者需自费进行ECS检测;76.2%(61/80)报告在检测前后提供咨询。

关键数值与推荐

  • 提供ECS的主要原因是使准父母能够做出知情的生殖决策以及预防父母的痛苦/负担。
  • 与已识别的携带者夫妇讨论的三种主要生殖选择为:胚胎植入前遗传学检测、使用供体配子和产前诊断检测。
  • 回复者遇到的挑战和道德困境主要围绕检测内容(包括变异分类和面板异质性)、咨询和检测费用。

临床怎么用

  • 作者认为该调查结果有助于识别医学辅助生殖领域ECS当前实践中的潜在挑战或改进领域,并促进关于如何应对这些挑战的讨论。

局限性

  • 尽管回复者总数可接受,但调查的完成率不理想。
  • 开放式问题的答案异质性、部分答案的模糊性以及不完整回复给调查结果的解读带来挑战。
  • 部分问题可能不易被回复者理解,因此回复偏倚和无回复偏倚被视为该调查的进一步局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the current practice and views on (expanded) carrier screening ((E)CS) among healthcare professionals in medically assisted reproductive (MAR) practices in Europe? SUMMARY ANSWER: The findings show a limited support for ECS with less than half of the respondents affiliated to centres offering ECS, and substantial variation in practice between centres in Europe. WHAT IS KNOWN ALREADY: The availability of next-generation sequencing, which enables testing for large groups of genes simultaneously, has facilitated the introduction and expansion of ECS strategies, currently offered particularly in the private sector in the context of assisted reproduction. STUDY DESIGN, SIZE, DURATION: A cross-sectional survey evaluating practice and current views among professionals working in MAR practice in different European countries was designed using the online SurveyMonkey tool. The web-based questionnaire included questions on general information regarding the current practice of (E)CS in MAR and questions on what is offered, to whom the test is offered, and how it is offered. It consisted mostly of multiple-choice questions with comment boxes, but also included open questions on the respondents' attitudes/concerns relevant to (E)CS practice, and room to upload requested files (e.g. guidelines and gene panels). In total, 338 responses were collected from 8 February 2022 to 11 April 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: The online survey was launched with an invitation email from the ESHRE central office (n = 4889 emails delivered) and the European Society of Human Genetics (ESHG) central office (n = 1790 emails delivered) sent to the ESHRE and ESHG members, and by social media posts. The survey was addressed to European MAR centres or gamete banks and to centres located in non-European countries participating in the European IVF-monitoring Consortium. Two reminder emails were sent. After exclusion of 39 incomplete responses received (e.g. only background information), 299 respondents from 40 different countries were included for analyses. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 42.5% (127/299) of respondents were affiliated to centres offering ECS. The perceived responsibility to enable prospective parents to make informed reproductive decisions and preventing suffering/burden for parents were the main reasons to offer ECS. A single ECS panel is offered by nearly 45% (39/87 received answers) of the centres offering ECS, 25.3% (22/87) of those centres offer a selection of ECS panels, and 29.9% (26/87) offer whole exome sequencing and a large in silico panel. Different ranges of panel sizes and conditions were included in the ECS panel(s) offered. Most of the respondents (81.8%; 72/88 received answers) indicated that the panels they offer are universal and target the entire population. Pathogenic variants (89.7%; 70/78 received answers), and to a lesser extent, likely pathogenic variants (64.1%%; 50/78 received answers), were included in the ECS report for individuals and couples undergoing MAR with their own gametes. According to 87.9% (80/91 received answers) of the respondents, patients have to pay to undergo an ECS test. Most respondents (76.2%; 61/80 received answers) reported that counselling is provided before and after the ECS test. Preimplantation genetic testing, the use of donor gametes, and prenatal diagnostic testing were the three main reproductive options discussed with identified carrier couples. The main reason, according to the respondents, for not offering ECS in their centre, was the lack of professional recommendations supporting ECS (52.5%; 73/139 received answers) and the high cost for couples or reimbursement not being available (49.6%; 69/139). The challenges and moral dilemmas encountered by the respondents revolved mainly around the content of the offer, including the variants classification and the heterogeneity of the panels, the counselling, and the cost of the test. LIMITATIONS, REASONS FOR CAUTION: Although the total number of respondents was acceptable, the completion rate of the survey was suboptimal. In addition, the heterogeneity of answers to open-ended questions and the ambiguity of some of the answers, along with incomplete responses, posed a challenge in interpreting survey results. It is also plausible that some questions were not easily understood by the respondents. For this reason, response and non-response bias are acknowledged as further limitations of the survey. WIDER IMPLICATIONS OF THE FINDINGS: The results of this survey could aid in identifying potential challenges or areas for improvement in the current practice of ECS in the MAR field and contribute to the discussion on how to address them. The results underline the need to stimulate a more knowledge-based debate on the complexity and the pros and cons of a possible implementation of ECS in MAR. STUDY FUNDING/COMPETING INTEREST(S): All costs relating to the development process were covered from European Society of Human Reproduction and Embryology and European Society of Human Genetics funds. There was no external funding of the development process or manuscript production. A.C. is full-time employee of Juno Genetics. L.H. declared receiving a research grant during the past 36 months from the Netherlands Organisation for Health Research and Development. She has also participated in a Health Council report of the Netherlands on preconception carrier screening and collaborated with the VSOP Dutch Genetic Alliance (patient umbrella organization on rare and genetic disorders). L.H. and C.v.E. are affiliated with Amsterdam University Medical Centre, a hospital that offers ECS in a non-commercial setting. R.V. received honoraria for presentations from Merck Academy and is unpaid board member of the executive committee of the Spanish Fertility Society. The other authors had nothing to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Capalbo A, de Wert G, Henneman L, et al. An ESHG-ESHRE survey on the current practice of expanded carrier screening in medically assisted reproduction. Hum Reprod. 2024. PMID: 38872341. doi:10.1093/humrep/deae131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。